111 related articles for article (PubMed ID: 37745510)
1. Interferon-Induced Bone Marrow Stromal Antigen 2 (BST2) Is A Functional Tumor-Initiating Cell Marker In Triple-Negative Breast Cancer.
Souto EP; Gong P; Landua JD; Srinivasan RR; Ganesan A; Dobrolecki LE; Purdy SC; Ford HL; Lewis MT
bioRxiv; 2023 Sep; ():. PubMed ID: 37745510
[TBL] [Abstract][Full Text] [Related]
2. STAT3 signaling is activated preferentially in tumor-initiating cells in claudin-low models of human breast cancer.
Wei W; Tweardy DJ; Zhang M; Zhang X; Landua J; Petrovic I; Bu W; Roarty K; Hilsenbeck SG; Rosen JM; Lewis MT
Stem Cells; 2014 Oct; 32(10):2571-82. PubMed ID: 24891218
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
4. Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.
Damelin M; Bankovich A; Park A; Aguilar J; Anderson W; Santaguida M; Aujay M; Fong S; Khandke K; Pulito V; Ernstoff E; Escarpe P; Bernstein J; Pysz M; Zhong W; Upeslacis E; Lucas J; Lucas J; Nichols T; Loving K; Foord O; Hampl J; Stull R; Barletta F; Falahatpisheh H; Sapra P; Gerber HP; Dylla SJ
Clin Cancer Res; 2015 Sep; 21(18):4165-73. PubMed ID: 26015513
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
[TBL] [Abstract][Full Text] [Related]
6. BST2 Mediates Osteoblast Differentiation via the BMP2 Signaling Pathway in Human Alveolar-Derived Bone Marrow Stromal Cells.
Yoo SH; Kim JG; Kim BS; Lee J; Pi SH; Lim HD; Shin HI; Cho ES; You HK
PLoS One; 2016; 11(6):e0158481. PubMed ID: 27359105
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow stromal cell antigen 2: Tumor biology, signaling pathway and therapeutic targeting (Review).
Yu H; Bian Q; Wang X; Wang X; Lai L; Wu Z; Zhao Z; Ban B
Oncol Rep; 2024 Mar; 51(3):. PubMed ID: 38240088
[TBL] [Abstract][Full Text] [Related]
8. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
9. MAP7D3, a novel prognostic marker for triple-negative breast cancer, drives cell invasiveness and cancer-initiating cell properties to promote metastatic progression.
Kuo WH; Chu PY; Wang CC; Huang PS; Chan SH
Biol Direct; 2023 Aug; 18(1):44. PubMed ID: 37550720
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer.
Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J
Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064
[TBL] [Abstract][Full Text] [Related]
11. Analysis of single-cell RNA-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer.
Shi Y; Huang X; Du Z; Tan J
Math Biosci Eng; 2022 Apr; 19(6):5793-5812. PubMed ID: 35603379
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
13. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
[TBL] [Abstract][Full Text] [Related]
14. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
15. ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells.
Leccia F; Del Vecchio L; Mariotti E; Di Noto R; Morel AP; Puisieux A; Salvatore F; Ansieau S
Mol Cancer; 2014 Sep; 13():213. PubMed ID: 25216750
[TBL] [Abstract][Full Text] [Related]
16. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
[TBL] [Abstract][Full Text] [Related]
17. Unraveling Heterogeneity of Tumor Cells and Microenvironment and Its Clinical Implications for Triple Negative Breast Cancer.
Jiang K; Dong M; Li C; Sheng J
Front Oncol; 2021; 11():557477. PubMed ID: 33854958
[No Abstract] [Full Text] [Related]
18. Kynurenine 3-monooxygenase upregulates pluripotent genes through β-catenin and promotes triple-negative breast cancer progression.
Huang TT; Tseng LM; Chen JL; Chu PY; Lee CH; Huang CT; Wang WL; Lau KY; Tseng MF; Chang YY; Chiang TY; Ueng YF; Lee HC; Dai MS; Liu CY
EBioMedicine; 2020 Apr; 54():102717. PubMed ID: 32268268
[TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA-sequencing uncovers compound kushen injection synergistically improves the efficacy of chemotherapy by modulating the tumor environment of breast cancer.
Liu X; Bai M; Li H; Ye P; Duan X; Wu C; Huang Z; Lu S; Zhang J; Zhao Z; Guo F; You R; Qin W; Wang W; Han A; Shen L; Wang Y; Zhao Z; Luo H; Wu J
Front Immunol; 2022; 13():965342. PubMed ID: 36389835
[TBL] [Abstract][Full Text] [Related]
20. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
